Department of Pharmaceutical Sciences, University of Toronto, Toronto, Ontario, Canada.
Nucl Med Biol. 2010 Feb;37(2):105-15. doi: 10.1016/j.nucmedbio.2009.10.001. Epub 2009 Nov 5.
The aims of this study were to (a) synthesize and characterize a novel vascular endothelial growth factor (VEGF-2K) recombinant protein expressed in Pichia pastoris and (b) compare its cytotoxicity when labeled with the Auger electron emitter (111)In or (99m)Tc, both of which are in the nanometer-micrometer range, toward porcine aortic endothelial (PAE) cells transfected with the flt-1 gene to overexpress Flt-1 receptors (PAE-Flt-1).
The gene for the VEGF(165) isoform was fused to a sequence encoding an extended flexible peptide (KGGGGSK) with two accessible lysines for preferential derivatization with diethylenetriaminepentaacetic acid (DTPA) for complexing (111)In and a sequence for a His(6) affinity tag that bound the (99m)Tc(CO)(3)(H(2)O)(3) tricarbonyl complex. P. pastoris strain KM71H was transfected with the recombinant gene, the VEGF-2K protein expressed with methanol induction, and then purified by metal-affinity chromatography. VEGF-2K was modified with 13-mer peptides [CGYGPKKKRKVGG] containing the nuclear localization sequence (NLS) of SV-40 large T-antigen (underlined) to promote nuclear uptake following its receptor-mediated internalization.
(99m)Tc-DTPA-VEGF-2K bound strongly and preferentially to PAE-Flt-1 cells compared with non-transfected PAE cells, but NLS modification diminished the ratio of PAE-Flt-1 to PAE binding to 2.3-fold. Nuclear accumulation of (99m)Tc-labeled DTPA-VEGF-2K was not enhanced by NLS modification but was enhanced by 1.5-fold for (111)In-DTPA-VEGF-2K-NLS. However, confocal microscopy revealed intranuclear distribution of DTPA-VEGF-2K-NLS, whereas DTPA-VEGF-2K distribution was mainly perinuclear. (111)In-DTPA-VEGF-2K-NLS was the most cytotoxic to PAE-Flt-1 cells, reducing their clonogenic survival by 4-fold. (111)In-DTPA-VEGF-2K, (99m)Tc-DTPA-VEGF-2K or (99m)Tc-DTPA-VEGF-2K-NLS had less effect on the clonogenic survival of PAE-Flt-1 or PAE cells. The strong cytotoxicity of (111)In-DTPA-VEGF-2K-NLS toward PAE-Flt-1 cells was associated with a 27-fold increase in nuclear foci of immunofluorescence for phosphorylated histone-2AX corresponding to sites of unrepaired DNA double-strand breaks. Monte Carlo modeling revealed that radionuclide decay in the nucleus would provide a 5-fold higher radiation absorbed dose for (111)In than for (99m)Tc, explaining their differential cytotoxicity, and intranuclear localization would amplify the radiation dose delivered by (111)In by 3-fold, explaining the greater potency of (111)In-DTPA-VEGF-2K-NLS compared with (111)In-DTPA-VEGF-2K.
We conclude that targeted Auger electron radiotherapy aimed at Flt-1 receptors is a promising strategy that should be explored further for treatment of tumors in which this angiogenic pathway is up-regulated. (111)In is a more cytotoxic radionuclide than (99m)Tc, unless DNA delivery can be achieved, due to the short range of the electrons emitted.
本研究旨在:(a) 合成和表征在巴斯德毕赤酵母中表达的新型血管内皮生长因子(VEGF-2K)重组蛋白;(b) 比较其在标记放射性核素 (111)In 或 (99m)Tc 时的细胞毒性,这两种核素均处于纳米至微米范围,对过表达 Flt-1 受体的转染猪主动脉内皮(PAE)细胞进行研究。
VEGF(165) 同工型的基因与一个编码延长的柔性肽(KGGGGSK)融合,该肽带有两个可及的赖氨酸,用于优先与二乙三胺五乙酸(DTPA)衍生化,以络合 (111)In,并带有 His(6)亲和标签序列,该序列结合 (99m)Tc(CO)(3)(H(2)O)(3)三羰基络合物。使用重组基因转染毕赤酵母 KM71H,用甲醇诱导表达 VEGF-2K 蛋白,然后通过金属亲和层析进行纯化。VEGF-2K 用 13 个氨基酸肽 [CGYGPKKKRKVGG] 进行修饰,该肽包含 SV-40 大 T 抗原的核定位序列(SV-40 大 T 抗原的核定位序列为下划线),以促进其受体介导的内化后的核摄取。
与非转染的 PAE 细胞相比,(99m)Tc-DTPA-VEGF-2K 与转染的 PAE-Flt-1 细胞结合牢固且优先结合,但 NLS 修饰将 PAE-Flt-1 与 PAE 结合的比率降低至 2.3 倍。NLS 修饰并没有增强放射性核素标记的 DTPA-VEGF-2K 的核积累,但增强了放射性核素标记的 DTPA-VEGF-2K-NLS 的核积累 1.5 倍。然而,共焦显微镜显示 DTPA-VEGF-2K-NLS 的核内分布,而 DTPA-VEGF-2K 的分布主要是核周的。(111)In-DTPA-VEGF-2K-NLS 对 PAE-Flt-1 细胞的细胞毒性最大,将其集落形成能力降低了 4 倍。(111)In-DTPA-VEGF-2K、(99m)Tc-DTPA-VEGF-2K 或 (99m)Tc-DTPA-VEGF-2K-NLS 对 PAE-Flt-1 或 PAE 细胞的集落形成能力影响较小。(111)In-DTPA-VEGF-2K-NLS 对 PAE-Flt-1 细胞的强烈细胞毒性与磷酸化组蛋白-2AX 的免疫荧光核焦点增加 27 倍相对应,这些焦点对应于未修复的 DNA 双链断裂的部位。蒙特卡罗建模显示,核内放射性核素衰变将为 (111)In 提供比 (99m)Tc 高 5 倍的辐射吸收剂量,解释了它们的差异细胞毒性,而核内定位将通过 (111)In 增加 3 倍的辐射剂量,解释了 (111)In-DTPA-VEGF-2K-NLS 与 (111)In-DTPA-VEGF-2K 相比的更大效力。
我们得出结论,靶向 Flt-1 受体的放射性电子放射治疗是一种很有前途的策略,应该进一步探索用于治疗该血管生成途径上调的肿瘤。与 (99m)Tc 相比,(111)In 是一种更具细胞毒性的放射性核素,除非可以实现 DNA 传递,因为发射的电子的射程较短。